Global Anti-hypertensive Drug Market Insights Forecasts to 2033

• The Global Anti-hypertensive Drug Market Size was Valued at USD 25 Billion in 2023.
• The Market Size is Growing at a CAGR of 7.18% from 2023 to 2033.
• The Worldwide Anti-hypertensive Drug Market Size is expected to Reach USD 50 Billion by 2033.
• Europe is expected to Grow the fastest during the forecast period.

The Global Anti-hypertensive Drug Market Size is expected to reach USD 50 Billion by 2033, at a CAGR of 7.18% during the forecast period 2023 to 2033

Hypertension is a long-term medical condition involving persistent elevation of arterial blood pressure. It is the major cause of premature death globally. Consumption of unhealthy diets, physical inactivity, tobacco and alcohol consumption, and obesity are some of the risk factors associated with hypertension. Other risk factors like kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular diseases are responsible for the rising prevalence of hypertension over the past few years. According to WHO, about 1.13 billion people are suffering from hypertension worldwide as per estimation of May 2021. The proper intake of anti-hypertensive medication is a central point in the management of hypertension. Choosing the right type of medicinal drug can be challenging, as considering the type of medication used depends on overall health condition and the extent of blood pressure. The effective anti-hypertensive treatment should be maintained indefinitely to reduce the relative risk of stroke and other cardiovascular disease events. The rising awareness related to hypertension diseases, increasing geriatric patients and rising inactive patients are the key factors responsible for boosting the market growth. The rising R&D of antihypertensive drugs is expected to thrive the market opportunity of anti-hypertensive drugs.             

Report Coverage

This research report categorizes the market for global anti-hypertensive drug market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global anti-hypertensive drug market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global anti-hypertensive drug market.

Driving Factors

The rising cases of diabetes, kidney diseases, obstructive sleep apnea, and other cardiovascular diseases increase the prevalence of hypertension which in turn increases the demand for anti-hypertensive drugs. The growing initiatives by government and private organizations and rising awareness regarding hypertension among people are likely to escalate the market growth of anti-hypertensive drugs. The launch of new and innovative therapeutics molecules is the key factor for the market growth of anti-hypertensive drugs. Additionally, the increase in geriatric patients is considered to be a prominent factor for boosting market growth.       

Restraining Factors        

The lack of awareness about the anti-hypertensive therapeutic regimes, particularly in developing countries restraining the market in that region. The associated side effects of anti-hypertensive drugs are likely to hinder the global anti-hypertensive drug market.

Market Segmentation

The global Anti-hypertensive drug market share is classified into Therapeutic Class, Distribution Channel, and Condition.

By Therapeutic Class Insights

The calcium channel blockers segment dominates the market with the largest revenue share over the forecast period.

On the basis of therapeutic class, the anti-hypertensive drug market is segmented into diuretics, ACE inhibitors, ARBs, beta-blockers, alpha-blockers, renin inhibitors, calcium channel blockers, and others. Among these, the calcium channel blockers segment is dominating the market with the largest revenue share over the forecast period. Calcium channel blockers effectively lower blood pressure by reducing calcium flux into cells leading to arterial dilation. It has fewer side effects as compared to other segments.

By Distribution channel Insights

The hospital pharmacy segment is witnessing significant CAGR growth over the forecast period.

On the basis of distribution channels, the global anti-hypertensive drug market is segmented into retail pharmacy, hospital pharmacy, e-commerce websites, online drug stores, and others. Among these, the hospital pharmacy segment is witnessing significant growth over the forecast period. There is a rise in a number of pharmacies and hypertensive drugs are mostly prescribed by specialized healthcare professionals available in hospitals augmenting the growth of the antihypertensive market.

By Type/Condition Insights

The primary hypertension segment is witnessing significant CAGR growth over the forecast period.

On the basis of condition, the global anti-hypertensive drug market is segmented into primary and secondary hypertension. Among these, primary hypertension is witnessing significant growth over the forecast period. It was found that 90-95% of hypertensive cases are of primary type due to nonspecific lifestyle and genetic factors. It is characterized by the elevation of blood pressure greater than 140/90mmHg with no specific etiology but may be due to obesity, family history, and an unhealthy diet. 

Regional Insights

North America dominates the market with the largest market share over the forecast period.

North America is dominating the market with the largest market share over the forecast period. North America holds the largest market share for anti-hypertensive drugs due to the high prevalence of hypertension in the region. Other factors include the need for rapid and accurate diagnosis and treatment of hypertension and the presence of technologically advanced healthcare infrastructure.  The advancement in healthcare infrastructure and management of disease prognosis in the region are driving the anti-hypertensive market.      

Europe is expected to grow the fastest during the forecast period. The growing initiatives by government and private organizations, increasing the awareness regarding hypertension are growing the market in Europe. Further, the growing anti-hypertensive drug market in Germany and UK contributes to escalate the market growth in Europe.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global anti-hypertensive drug market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market

List of Key Market Players

• Abbott Laboratories
• AstraZeneca Plc.
• Dr. Reddy’s Laboratories
• Sanofi
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• Medtronic Inc.
• GlaxoSmithKline Plc.
• Stryker Corporation
• Orthofix
• Takeda Pharmaceutical Co.
• Bayer AG
• Noden Pharma DAC
• Others

Recent Developments

• In September 2022, Korea Hanmi launched a high-blood pressure blockbuster drug Amosartan in China under the brand name Meiyaping. Amosartan is a combination of Amlodipine camsylate (Calcium channel blocker) and Losartan potassium (Angiotensin II receptor blocker). 

• In December 2021, Dr Reddy Laboratories launched a drug Valsartan tablet to treat high blood pressure, and heart failure in the US market. The Valsartan tablet is the generic therapeutic equivalent of Diovan, an angiotensin II receptor blocker.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global anti-hypertensive drug market based on the below-mentioned segments:

Anti-hypertensive Drug Market, Therapeutic Class Analysis

• Diuretics
• ACE inhibitors
• ARBs
• Beta-blockers
• Alpha-blockers
• Renin inhibitors
• Calcium channel blocker
• Others

Anti-hypertensive Drug Market, Distribution Channel Analysis

• Retail Pharmacy
• Hospital Pharmacy
• E-commerce website
• Online Drug Stores
• Others

Anti-hypertensive Drug Market, Type/Condition Analysis

• Primary hypertension
• Secondary hypertension

Anti-hypertensive drug Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa